|
Fusion gene ID: 20801 |
FusionGeneSummary for MAP2K2_INSR |
Fusion gene summary |
Fusion gene information | Fusion gene name: MAP2K2_INSR | Fusion gene ID: 20801 | Hgene | Tgene | Gene symbol | MAP2K2 | INSR | Gene ID | 5605 | 3643 |
Gene name | mitogen-activated protein kinase kinase 2 | insulin receptor | |
Synonyms | CFC4|MAPKK2|MEK2|MKK2|PRKMK2 | CD220|HHF5 | |
Cytomap | 19p13.3 | 19p13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | dual specificity mitogen-activated protein kinase kinase 2ERK activator kinase 2MAP kinase kinase 2MAPK/ERK kinase 2mitogen-activated protein kinase kinase 2, p45 | insulin receptorIR | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | P36507 | P06213 | |
Ensembl transtripts involved in fusion gene | ENST00000262948, ENST00000394867, ENST00000599345, | ENST00000341500, ENST00000302850, | |
Fusion gene scores | * DoF score | 8 X 4 X 6=192 | 13 X 10 X 6=780 |
# samples | 7 | 15 | |
** MAII score | log2(7/192*10)=-1.45567948377619 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(15/780*10)=-2.37851162325373 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: MAP2K2 [Title/Abstract] AND INSR [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation | Oncogene involved fusion gene, in-frame and retained their domain. Kinase involved fusion gene, inframe and retained kinase domain. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | MAP2K2 | GO:0036289 | peptidyl-serine autophosphorylation | 8388392 |
Hgene | MAP2K2 | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 8388392 |
Tgene | INSR | GO:0001934 | positive regulation of protein phosphorylation | 7556070 |
Tgene | INSR | GO:0007186 | G-protein coupled receptor signaling pathway | 9092559 |
Tgene | INSR | GO:0008284 | positive regulation of cell proliferation | 17925406 |
Tgene | INSR | GO:0008286 | insulin receptor signaling pathway | 6849137|8440175|20455999 |
Tgene | INSR | GO:0018108 | peptidyl-tyrosine phosphorylation | 8496180 |
Tgene | INSR | GO:0032148 | activation of protein kinase B activity | 7556070 |
Tgene | INSR | GO:0032869 | cellular response to insulin stimulus | 8440175 |
Tgene | INSR | GO:0043410 | positive regulation of MAPK cascade | 20455999 |
Tgene | INSR | GO:0045725 | positive regulation of glycogen biosynthetic process | 17925406 |
Tgene | INSR | GO:0046326 | positive regulation of glucose import | 3518947 |
Tgene | INSR | GO:0046777 | protein autophosphorylation | 6849137|8496180 |
Tgene | INSR | GO:0051290 | protein heterotetramerization | 1898103 |
Tgene | INSR | GO:0060267 | positive regulation of respiratory burst | 9092559 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | OV | TCGA-13-1410-01A | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000262948 | ENST00000341500 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
In-frame | ENST00000262948 | ENST00000302850 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
Frame-shift | ENST00000394867 | ENST00000341500 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
Frame-shift | ENST00000394867 | ENST00000302850 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
5UTR-3CDS | ENST00000599345 | ENST00000341500 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
5UTR-3CDS | ENST00000599345 | ENST00000302850 | MAP2K2 | chr19 | 4110507 | - | INSR | chr19 | 7132328 | - |
Top |
FusionProtFeatures for MAP2K2_INSR |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MAP2K2 | INSR |
Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}. | Receptor tyrosine kinase which mediates the pleiotropicactions of insulin. Binding of insulin leads to phosphorylation ofseveral intracellular substrates, including, insulin receptorsubstrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signalingintermediates. Each of these phosphorylated proteins serve asdocking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognizedifferent phosphotyrosine residues, including the p85 regulatorysubunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead tothe activation of two main signaling pathways: the PI3K-AKT/PKBpathway, which is responsible for most of the metabolic actions ofinsulin, and the Ras-MAPK pathway, which regulates expression ofsome genes and cooperates with the PI3K pathway to control cellgrowth and differentiation. Binding of the SH2 domains of PI3K tophosphotyrosines on IRS1 leads to the activation of PI3K and thegeneration of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3),a lipid second messenger, which activates several PIP3-dependentserine/threonine kinases, such as PDPK1 and subsequently AKT/PKB.The net effect of this pathway is to produce a translocation ofthe glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles tothe cell membrane to facilitate glucose transport. Moreover, uponinsulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD;regulates the expression of gluconeogenic and lipogenic enzymes bycontrolling the activity of the winged helix or forkhead (FOX)class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulatescell growth and metabolism and integrates signals from insulin.AKT mediates insulin-stimulated protein synthesis byphosphorylating TSC2 thereby activating mTORC1 pathway. TheRas/RAF/MAP2K/MAPK pathway is mainly involved in mediating cellgrowth, survival and cellular differentiation of insulin.Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers theactivation of the Ras/RAF/MAP2K/MAPK pathway. In addition tobinding insulin, the insulin receptor can bind insulin-like growthfactors (IGFI and IGFII). Isoform Short has a higher affinity forIGFII binding. When present in a hybrid receptor with IGF1R, bindsIGF1. PubMed:12138094 shows that hybrid receptors composed ofIGF1R and INSR isoform Long are activated with a high affinity byIGF1, with low affinity by IGF2 and not significantly activated byinsulin, and that hybrid receptors composed of IGF1R and INSRisoform Short are activated by IGF1, IGF2 and insulin. Incontrast, PubMed:16831875 shows that hybrid receptors composed ofIGF1R and INSR isoform Long and hybrid receptors composed of IGF1Rand INSR isoform Short have similar binding characteristics, bothbind IGF1 and have a low affinity for insulin.{ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505,ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688,ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530,ECO:0000269|PubMed:9428692}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | MAP2K2 | chr19:4110507 | chr19:7132328 | ENST00000262948 | - | 3 | 11 | 78_86 | 150 | 401 | Nucleotide binding | ATP |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 1023_1298 | 894 | 1383 | Domain | Protein kinase |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 1023_1298 | 882 | 1371 | Domain | Protein kinase |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 1104_1110 | 894 | 1383 | Nucleotide binding | ATP |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 1163_1164 | 894 | 1383 | Nucleotide binding | ATP |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 1104_1110 | 882 | 1371 | Nucleotide binding | ATP |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 1163_1164 | 882 | 1371 | Nucleotide binding | ATP |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 1361_1364 | 894 | 1383 | Region | Note=PIK3R1-binding |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 1361_1364 | 882 | 1371 | Region | Note=PIK3R1-binding |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 980_1382 | 894 | 1383 | Topological domain | Cytoplasmic |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 980_1382 | 882 | 1371 | Topological domain | Cytoplasmic |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 957_979 | 894 | 1383 | Transmembrane | Helical |
Tgene | >INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 957_979 | 882 | 1371 | Transmembrane | Helical |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | >MAP2K2 | chr19:4110507 | chr19:7132328 | ENST00000262948 | - | 3 | 11 | 266_315 | 150 | 401 | Compositional bias | Note=Pro-rich |
Hgene | >MAP2K2 | chr19:4110507 | chr19:7132328 | ENST00000262948 | - | 3 | 11 | 72_369 | 150 | 401 | Domain | Protein kinase |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 182_339 | 894 | 1383 | Compositional bias | Note=Cys-rich |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 28_174 | 894 | 1383 | Compositional bias | Note=Leu-rich |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 182_339 | 882 | 1371 | Compositional bias | Note=Cys-rich |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 28_174 | 882 | 1371 | Compositional bias | Note=Leu-rich |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 624_726 | 894 | 1383 | Domain | Fibronectin type-III 1 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 757_842 | 894 | 1383 | Domain | Fibronectin type-III 2 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 853_947 | 894 | 1383 | Domain | Fibronectin type-III 3 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 624_726 | 882 | 1371 | Domain | Fibronectin type-III 1 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 757_842 | 882 | 1371 | Domain | Fibronectin type-III 2 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 853_947 | 882 | 1371 | Domain | Fibronectin type-III 3 |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 733_741 | 894 | 1383 | Region | Note=Insulin-binding |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 733_741 | 882 | 1371 | Region | Note=Insulin-binding |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 28_758 | 894 | 1383 | Topological domain | Extracellular |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000302850 | - | 12 | 22 | 763_956 | 894 | 1383 | Topological domain | Extracellular |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 28_758 | 882 | 1371 | Topological domain | Extracellular |
Tgene | INSR | chr19:4110507 | chr19:7132328 | ENST00000341500 | - | 11 | 21 | 763_956 | 882 | 1371 | Topological domain | Extracellular |
Top |
FusionGeneSequence for MAP2K2_INSR |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
>In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000341500_chr19_7132328_-_639aa MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQ HRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMELHLCVSRKHFALERGCRLRGLSPGNYSVR IRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPD EWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVME LMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGG KGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFL EIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRIL >In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000302850_chr19_7132328_-_639aa MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQ HRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMELHLCVSRKHFALERGCRLRGLSPGNYSVR IRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPD EWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVME LMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGG KGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFL EIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRIL |
* Fusion transcript sequences (only coding sequence (CDS) region). |
>In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000341500_chr19_7132328_-_1917nt ATGCTGGCCCGGAGGAAGCCGGTGCTGCCGGCGCTCACCATCAACCCTACCATCGCCGAGGGCCCATCCCCTACCAGCGAGGGCGCCTCC GAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACCCAG AAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTCCAG CACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTGCAG GTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACACATG GAGCTGCATCTCTGCGTCTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAACTACAGCGTGCGA ATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATT GCAAAAATTATCATCGGCCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGAAAGAGGCAGCCA GATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTCAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGAC GAGTGGGAGGTGTCTCGAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGCAATGCCAGGGAC ATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAG GCCTCGGTCATGAAGGGCTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTGGTGGTGATGGAG CTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCAGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAA GAGATGATTCAGATGGCGGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTGGCAGCGAGAAAC TGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGC AAGGGTCTGCTCCCTGTACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGGTCCTTTGGCGTG GTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTGTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTAT CTGGATCAACCCGACAACTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGGCCAACCTTCCTG GAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAGGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGT GAGGAGCTGGAGATGGAGTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCGGGGGGCCGGGAT GGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCTTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTG >In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000302850_chr19_7132328_-_1917nt ATGCTGGCCCGGAGGAAGCCGGTGCTGCCGGCGCTCACCATCAACCCTACCATCGCCGAGGGCCCATCCCCTACCAGCGAGGGCGCCTCC GAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACCCAG AAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTCCAG CACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTGCAG GTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACACATG GAGCTGCATCTCTGCGTCTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAACTACAGCGTGCGA ATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATT GCAAAAATTATCATCGGCCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGAAAGAGGCAGCCA GATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTCAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGAC GAGTGGGAGGTGTCTCGAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGCAATGCCAGGGAC ATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAG GCCTCGGTCATGAAGGGCTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTGGTGGTGATGGAG CTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCAGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAA GAGATGATTCAGATGGCGGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTGGCAGCGAGAAAC TGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGC AAGGGTCTGCTCCCTGTACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGGTCCTTTGGCGTG GTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTGTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTAT CTGGATCAACCCGACAACTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGGCCAACCTTCCTG GAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAGGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGT GAGGAGCTGGAGATGGAGTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCGGGGGGCCGGGAT GGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCTTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTG |
* Fusion transcript sequences (Full-length transcript). |
>In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000341500_chr19_7132328_-_6972nt CCCCTGCCTCTCGGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGCCCCAGCGCCCCTC GGCTACCCTCGGCCCAGGCCCGCAGCGCCGCCCGCCCTCGGCCGCCCCGACGCCGGCCTGGGCCGCGGCCGCAGCCCCGGGCTCGCGTAG GCGCCGACCGCTCCCGGCCCGCCCCCTATGGGCCCCGGCTAGAGGCGCCGCCGCCGCCGGCCCGCGGAGCCCCGATGCTGGCCCGGAGGA AGCCGGTGCTGCCGGCGCTCACCATCAACCCTACCATCGCCGAGGGCCCATCCCCTACCAGCGAGGGCGCCTCCGAGGCAAACCTGGTGG ACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACCCAGAAAGCCAAGGTCGGCG AACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTCCAGCACAGACCCTCGGGCC TCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTGCAGGTCCTGCACGAATGCA ACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACACATGGAGCTGCATCTCTGCG TCTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAACTACAGCGTGCGAATCCGGGCCACCTCCC TTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCG GCCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGAAAGAGGCAGCCAGATGGGCCGCTGGGAC CGCTTTACGCTTCTTCAAACCCTGAGTATCTCAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTC GAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGCAATGCCAGGGACATCATCAAGGGTGAGG CAGAGACCCGCGTGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGG GCTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTGGTGGTGATGGAGCTGATGGCTCACGGAG ACCTGAAGAGCTACCTCCGTTCTCTGCGGCCAGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGG CGGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTGGCAGCGAGAAACTGCATGGTCGCCCATG ATTTTACTGTCAAAATTGGAGACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTG TACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGGTCCTTTGGCGTGGTCCTTTGGGAAATCA CCAGCTTGGCAGAACAGCCTTACCAAGGCCTGTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACA ACTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGGCCAACCTTCCTGGAGATTGTCAACCTGC TCAAGGACGACCTGCACCCCAGCTTTCCAGAGGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGG AGTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCGGGGGGCCGGGATGGAGGGTCCTCGCTGG GTTTCAAGCGGAGCTACGAGGAACACATCCCTTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCA ATCCTTCCTAACAGTGCCTACCGTGGCGGGGGCGGGCAGGGGTTCCCATTTTCGCTTTCCTCTGGTTTGAAAGCCTCTGGAAAACTCAGG ATTCTCACGACTCTACCATGTCCAATGGAGTTCAGAGATCGTTCCTATACATTTCTGTTCATCTTAAGGTGGACTCGTTTGGTTACCAAT TTAACTAGTCCTGCAGAGGATTTAACTGTGAACCTGGAGGGCAAGGGGTTTCCACAGTTGCTGCTCCTTTGGGGCAACGACGGTTTCAAA CCAGGATTTTGTGTTTTTTCGTTCCCCCCACCCGCCCCCAGCAGATGGAAAGAAAGCACCTGTTTTTACAAATTCTTTTTTTTTTTTTTT TTTTTTGCTGGTGTCTGAGCTTCAGTATAAAAGACAAAACTTCCTGTTTGTGGAACAAAAGTTCGAAAGAAAAAACAAAACAAAAACACC CAGCCCTGTTCCAGGAGAATTTCAAGTTTTACAGGTTGAGCTTCAAGATGGTTTTTTTGGTTTTTTTTTTTTCTCTCATCCAGGCTGAAG GATTTTTTTTTTCTTTACAAAATGAGTTCCTCAAATTGACCAATAGCTGCTGCTTTCATATTTTGGATAAGGGTCTGTGGTCCCGGCGTG TGCTCACGTGTGTATGCACGTGTGTGTGTCCATTAGACACGGCTGATGTGTGTGCAAAGTATCCATGCGGAGTTGATGCTTTGGGAATTG GCTCATGAAGGTTCTTCTCAAGGGTGCGAGCTCATCCCCCTCTCTCCTTCCTTCTTATTGACTGGGAGACTGTGCTCTCGACAGATTCTT CTTGTGTCAGAAGTCTAGCCTCAGGTTTCTACCCTCCCTTCACATTGGTGGCCAAGGGAGGAGCATTTCATTTGGAGTGATTATGAATCT TTTCAAGACCAAACCAAGCTAGGACATTAAAAAAAAAAAAAGAAAAAGAAAGAAAAAACAAAATGGAAAAAGGAAAAAAAAAAAGAACTG AGATGACAGAGTTTTGAGAATATATTTGTACCATATTTAATTTTTAAAGTCTCTGGTATTAGCCTCATAAGTTATTGACTATTCCCCGGG GTTGGCGGGGAGTGGGGACATGAGTTGGTCTGCCTGTTGTGGGGCCGGGAAGGGGAGGGAGTCAGGCACAAGTGGCCTCTTTGTTTGGTC TTAAAGGCATCCATTTCTGGGAATGAAGCCATGTTCGCTGCTAACACTTTTGGATGTTGTGAGGCCACGTGGAGTGTGTGAGAGACTAGG TTTTATGGATGGTCTGGTTCAGGTACCAGGTCTGCTGGAAGGTTCCTGTTCGGATAAGCTGGTAGCTACCTAGCTCTGAGCCTGCCTTCA AGAACACCTGTGTTCATCCTCTGATTCTCTGTGTGTACCTCTTGTGGCGTTTCCTCTCCCGGGTGTGAACATCCTAACCGTTATTGTGCA AACCCAAGAACGTCAGATCCCAAAGCACAACAACCTGGATGGACTTTGGGAACATCTAAGCAATGTAAGAGAGAGGTGCACTGAGAGTAC GTCTTGGTCCCCTCCACCCTGAGAGCATCTGACGGTCCTCAGTACTGAACTCCCGGAAGCTGCTCTGAGCCCGGTGACCTCATCTGGGCC AGGTGTGGTGCCTGAGCTGAATGCTCAGGTGCTTACAGTGTTGCAATCCCTAAGAGAGTAGAGTCTGGAGGAGAAACCGTGAAAAAGACC TTACACACCACCAAGAACTTCCGAATGGGCGTGAATCCACCGTTTCTTCTCTTTGCAAAAAGAACCACCACAGCTGCTCAAAGAACACAG TGAACTCATCACTTTGGTTCATCAAAAAATCATCGCCCATGCGTTATTCCTGAGTGCATTTTCTTACAACTTTTTGACTGCTTCCTTTTC TTCTTCTCTTAAGAGTTGTGGGCTTAAGAATGGGATAGAGTCATAATGGCAACCTCCAAGCCCTCTCAATTCTTGATTAAGAACACAGGT AGACATGAATCCCAATTGTCTATTGCTATCTTATTTATATGATTCGGGAAAATACAGCATGTAAAAATATTGCTGAGGAGCCTCAGTGAT TGGGTACAAGAAGCAAGAGTACAGAAATTATTTTTGCCAAATTTATTTTGTAAATATGAGGGTCTGTACCTAAATTTAAAAAAAAAACAC GTAGAACTAGGTATTTTGTTCTCTTCTTAGTAAATTTGTAGTGGTTGTATACTACACTAGCTGCAATTTTCACATTTTTCTAATTCAGAA AGGTTTTTCTTATATTAGGGGAAAAAGTATTTATTTTAATATATAAAATCACTCTGAAAATCACTCTCATAAAAAATGGAGCGCATGTAA ATTTTTATCAAAGAAAAATAAACAGGTGAATGGGGGATAGTGATTTTCTTTTTTCAGCACAGTCTACCTCAGTGTATTGTTAAGATGTGA TTCAATCATGGACATCTTTGAGATTTCAGAATTCTACCTGGAACCGGTCTGAATCAGGGAACGTGTGTATCAGCTGATTCGAATGCCAGG GACCAGTAAGAATTTTGAGGGAGGGAGTTGGGATGGAGAAGGTATGGCCTTTATGCGAGCATAGATCCTTTTCTTCCTGGCTGGTAATAT TCTTCTCTGAATTTAATCTTCCTTTAAAAAAAAATCCTCCATCTATTGTCACTATGTTCCCCAAACATAAACTAAGTTCCAGGCTGTCAT GATGTATCTGATATATGGGGTAACCCAGCAAGGTGTACCTTCCTTTGGTGAGAGATGGCTGCCGGGGCAAAGACGGGCTTTGATTCAGAG CAAGCATTCCCACCTGTTCCATGGAATCCCCCTGAAGTGAGCACAAAGGTGCCCTGGGCTCCCTGATGGTTTATGCCCACTCCTTTCAGG CTGGTGATGCACCTTACACACAAACACCTAATGCAATGTCTTTTTAAATTCTCCAAGTGGGATGGGAGCATGTGAGGGAAATTCCAATCC AAAACCCATTAATGTGCTGAACGCTTTTTTTTTTTTTTTTTTTTTTTTTGCAACAACACCTTGGACCTCTGTGTTGGGGTTTGACTGACC TCAAGCTGATATTATTGGACCTTGTGCAGCTTTGATAACCCATGTGAGAGTCTAGGCAGGACCAGTGGGGCCCAAATCTTGCTGCTCTTG TACTTTTAGGCACTGCCCTTGCAGACTCACCTTTCTCCACCTGCCCTGGAGAAAGGTAGGGTGTGCTGGGCCTGCCCCTTGCAAATGGGA TTCACCAGTTTCATTTATTTGACTCTACTGCCACAGTGAAAAGAGCAAACAGCTATTGGGTTGCAAACCTCCTTTGACATTAGGAAATGT TGACTTTGTAACAATAAAACTTTGGTCCTAGAAAGACACGGTTGTCCTGGGAGTTTGTAGTGTTAAGTTGCAACAACAACAACAAAAAGC AACAAAACCAGCTTAGGATAACACTTTTTGTTGCTTGTTCTTAAAGATGTCTCACTATGATTAAAACCCTTTTCATTAATGTAGTGAAAG CCACACAGGAGTTCCTTCTTCCAGGAGGAGAATACCAAGCACATCACTTTCTCTCTGCATCAGTGATGTCAAATACGCATCAGAAAATGT TCAGGTTTTAGGAGCTGTCCTAGGTGCTGTTTCATCATTGGAAGCAGTGAGAAAGAGAAGCACTGCTGCTTGTCTGGATATAGGCTGAGG ATGATTGAGAGAAGCTGTGGGAACTGACACAAGGGTCTGCATAGGTCATCCTGTGACCCTGGGGACTATGTTACCAACTGACAGACAGAT CTTTCACTGTATCCTAGCAGGGCAGGTAGTCCACCAAGAAATGTGCTTATTGGATTGGGAGGTGTTTATTTGTAGTCTGCTGTAACACGT GTGAAAGAGCAGGAGCGTCATCAGCATATGACTTGCGCTGGTCATCCGGTAAATGGATGTGCTGTAGTCCCAGTGCTAATCATTTCTCTC CTTCACAGTGGGTGGAAGTTTAGGGTTAAATGTCCTTTGAATGTCACCTGGTGAGTCCTTGACACCTTAGGCTCTTCAGAAACAATGGTT TTGTTGAGGATGGGGAACAGGGAATGCCGATTTTATATACATGGTACACAGAGAGGGGTGTCACTTCAGAAAATCTTCCAGCATGTTCTT CAGAATATTAATTTATATGCGAGGTGAGGTTGGGAATGAAAAGAACAGGTCAGCACTTTTTTTTTTCCTAGAACATACAAAAGAACATGG TGGACTTTCAGGGAGTGCAATGGAAGGTGAATATTTCCTTAAGGGTCCCCGAGAAATGGGAGTGAGGGGAGGGGACACAATGGCTTTTTG AGCTTACTTTTACCTTCTGATACTAGTCAAGGTCCAGAACCAGCCACCAGCCAAATTTCTATCTGGGTGCGGGCCACTGAAAATCCTTGT TAAAAACCAGATCACAAATCTGGGGCTCTTGGTCCCATTGGAGAAGGAAGGAAGAGCCTCAAAATAAGTGTGCACCCATGCACATATTCA GGAACAGCTTGTTTAGTCTTTACACTTTGCCTGAAAGTTGCTTCTCCTCGTCCCTTTGTGTGCCTGGGTGGCCTCGGCCCTGTGCGTTGG CAACGCAGGATCAAATGTGCTGCAGCTTTTGCAGAAAACAACTCAGAAACACAAAACCCCCCAACAGCTCAATTATTATTTTTTCAATGT TTTCCTACAAGAGCCAAGTAGCACCATGTACAGAAGACGCCTTTTTTTTTGGAATATTGAAATCGTTCTGCATGTAAAATATGGGATAAT >In-frame_MAP2K2_ENST00000262948_chr19_4110507_-_INSR_ENST00000302850_chr19_7132328_-_2600nt CCCCTGCCTCTCGGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGCCCCAGCGCCCCTC GGCTACCCTCGGCCCAGGCCCGCAGCGCCGCCCGCCCTCGGCCGCCCCGACGCCGGCCTGGGCCGCGGCCGCAGCCCCGGGCTCGCGTAG GCGCCGACCGCTCCCGGCCCGCCCCCTATGGGCCCCGGCTAGAGGCGCCGCCGCCGCCGGCCCGCGGAGCCCCGATGCTGGCCCGGAGGA AGCCGGTGCTGCCGGCGCTCACCATCAACCCTACCATCGCCGAGGGCCCATCCCCTACCAGCGAGGGCGCCTCCGAGGCAAACCTGGTGG ACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACCCAGAAAGCCAAGGTCGGCG AACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTCCAGCACAGACCCTCGGGCC TCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTGCAGGTCCTGCACGAATGCA ACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACACATGGAGCTGCATCTCTGCG TCTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAACTACAGCGTGCGAATCCGGGCCACCTCCC TTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCG GCCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGAAAGAGGCAGCCAGATGGGCCGCTGGGAC CGCTTTACGCTTCTTCAAACCCTGAGTATCTCAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTC GAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGCAATGCCAGGGACATCATCAAGGGTGAGG CAGAGACCCGCGTGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGG GCTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTGGTGGTGATGGAGCTGATGGCTCACGGAG ACCTGAAGAGCTACCTCCGTTCTCTGCGGCCAGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGG CGGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTGGCAGCGAGAAACTGCATGGTCGCCCATG ATTTTACTGTCAAAATTGGAGACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTG TACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGGTCCTTTGGCGTGGTCCTTTGGGAAATCA CCAGCTTGGCAGAACAGCCTTACCAAGGCCTGTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACA ACTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGGCCAACCTTCCTGGAGATTGTCAACCTGC TCAAGGACGACCTGCACCCCAGCTTTCCAGAGGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGG AGTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCGGGGGGCCGGGATGGAGGGTCCTCGCTGG GTTTCAAGCGGAGCTACGAGGAACACATCCCTTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCA ATCCTTCCTAACAGTGCCTACCGTGGCGGGGGCGGGCAGGGGTTCCCATTTTCGCTTTCCTCTGGTTTGAAAGCCTCTGGAAAACTCAGG ATTCTCACGACTCTACCATGTCCAATGGAGTTCAGAGATCGTTCCTATACATTTCTGTTCATCTTAAGGTGGACTCGTTTGGTTACCAAT TTAACTAGTCCTGCAGAGGATTTAACTGTGAACCTGGAGGGCAAGGGGTTTCCACAGTTGCTGCTCCTTTGGGGCAACGACGGTTTCAAA CCAGGATTTTGTGTTTTTTCGTTCCCCCCACCCGCCCCCAGCAGATGGAAAGAAAGCACCTGTTTTTACAAATTCTTTTTTTTTTTTTTT |
Top |
FusionGenePPI for MAP2K2_INSR |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
MAP2K2 | ARAF, MAPK3, MAPK1, MAP2K2, MEPCE, COPS5, YWHAB, MAP2K1, WDR83, RAF1, MAPK8, LIG4, BRAF, PEX14, ZNF207, FAM65B, IQGAP1, NFE2L2, EGFR, CCNDBP1, ART3, ACTL6A, TNF, PDLIM5, RPE, TXN, XPO1, SNW1, HSP90AA4P, HSP90AB3P, HSP90AB4P, HSP90AA5P, SERPINB2, HSPA8, TUBA4A, CD70, CCRN4L, DLD, TRIM25 | INSR | CSK, IRS1, FRS2, SOCS3, IRS2, GRB10, MAPK1, MAPK3, AHSG, KHDRBS1, PTPN11, PTPN6, ENPP1, HRAS, CAV1, GRB2, SMAD2, PRKCD, VAV3, INSRR, SH2B1, INPPL1, SNX6, SNX1, SNX2, SNX4, RASA1, JAK2, VAV1, GRB7, SHC1, SYNCRIP, GRB14, PTPN1, SORBS1, SH2B2, HGS, SOCS1, SOCS6, PLCG1, STAT5A, STAT5B, JAK1, DOK1, IRF7, TEAD1, MOK, ARRB2, KRT31, SNX17, SNX27, SQSTM1, ATIC, PTPLAD1, PRKAA1, PRKAA2, KIF5A, PTPRK, PON2, NTRK1, TMEM17, MARCH1, PPM1A, PPM1F, PTPRR, DUSP18, MPZL2, SSH1, UNC5CL, FAM19A4, SCGB1D1, CLEC3A, FAM19A3, INSL5, DNASE1L2, DUSP19, STYX, TRIM25, INSR, ACP1 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MAP2K2_INSR |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | MAP2K2 | P36507 | DB06616 | Bosutinib | Dual specificity mitogen-activated protein kinase kinase 2 | small molecule | approved |
Hgene | MAP2K2 | P36507 | DB08911 | Trametinib | Dual specificity mitogen-activated protein kinase kinase 2 | small molecule | approved |
Tgene | INSR | P06213 | DB00046 | Insulin Lispro | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB00047 | Insulin Glargine | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB00071 | Insulin Pork | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB01306 | Insulin Aspart | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB01307 | Insulin Detemir | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB01309 | Insulin Glulisine | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB09564 | Insulin Degludec | Insulin receptor | biotech | approved |
Tgene | INSR | P06213 | DB00030 | Insulin Human | Insulin receptor | biotech | approved|investigational |
Tgene | INSR | P06213 | DB01277 | Mecasermin | Insulin receptor | biotech | approved|investigational |
Top |
RelatedDiseases for MAP2K2_INSR |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | MAP2K2 | C3809007 | CARDIOFACIOCUTANEOUS SYNDROME 4 | 3 | UNIPROT |
Hgene | MAP2K2 | C1275081 | Cardio-facio-cutaneous syndrome | 2 | CTD_human;ORPHANET |
Hgene | MAP2K2 | C0010606 | Adenoid Cystic Carcinoma | 1 | CTD_human |
Hgene | MAP2K2 | C0025202 | melanoma | 1 | CTD_human |
Hgene | MAP2K2 | C0028326 | Noonan Syndrome | 1 | CTD_human |
Hgene | MAP2K2 | C0587248 | Costello syndrome (disorder) | 1 | CTD_human |
Tgene | INSR | C0342278 | Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans | 18 | CTD_human;UNIPROT |
Tgene | INSR | C0265344 | Donohue Syndrome | 14 | CTD_human;ORPHANET;UNIPROT |
Tgene | INSR | C0271695 | Rabson-Mendenhall Syndrome | 7 | ORPHANET;UNIPROT |
Tgene | INSR | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 3 | HPO;UNIPROT |
Tgene | INSR | C1864952 | Hyperinsulinemic Hypoglycemia, Familial, 5 | 3 | CTD_human;ORPHANET;UNIPROT |
Tgene | INSR | C0011853 | Diabetes Mellitus, Experimental | 2 | CTD_human |
Tgene | INSR | C0020459 | Hyperinsulinism | 2 | CTD_human;HPO |
Tgene | INSR | C0021655 | Insulin Resistance | 2 | CTD_human |
Tgene | INSR | C0024115 | Lung diseases | 2 | CTD_human |
Tgene | INSR | C0002395 | Alzheimer's Disease | 1 | CTD_human |
Tgene | INSR | C0011882 | Diabetic Neuropathies | 1 | CTD_human |
Tgene | INSR | C0020429 | Hyperalgesia | 1 | CTD_human |
Tgene | INSR | C0020456 | Hyperglycemia | 1 | CTD_human;HPO |
Tgene | INSR | C0030567 | Parkinson Disease | 1 | CTD_human |
Tgene | INSR | C0235833 | Congenital diaphragmatic hernia | 1 | CTD_human |
Tgene | INSR | C0236969 | Substance-Related Disorders | 1 | CTD_human |
Tgene | INSR | C0271650 | Impaired glucose tolerance | 1 | CTD_human |
Tgene | INSR | C0752347 | Lewy Body Disease | 1 | CTD_human |